Serum paraoxonase level and paraoxonase polymorphism in patients with acromegaly.

ABSTRACT:

Background

Acromegalic patients have increased cardiometabolic risk factors due to an elevation of growth hormone (GH) levels. Human serum paraoxonase (PON), a high-density lipoprotein (HDL)-related enzyme, is one of the major bioscavengers and decreases the oxidation of low-density lipoprotein (LDL), a key regulator in the pathogenesis of atherosclerosis. In this study, we investigated a potential relationship between serum PON levels or PON polymorphisms and acromegaly.

Methods

A total of 48 acromegalic patients and 44 healthy controls were included in this study. Serum GH levels, insulin-like growth factor-1 levels and lipid profiles were measured. Serum PON levels, as well as PON 1 L55M and Q192R gene polymorphisms, were examined.

Results

No significant difference

SUBMITTER: Arpaci D 

PROVIDER: S-EPMC6837684 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature